尿激酶溶栓联合替罗非班或替格瑞洛抗血小板治疗急性ST段抬高型心肌梗死效果分析

doi:10.3969/j.issn.1006-6233.2017.09.011

Abstract
Figure/Table
References
Related Citation (4)

Download: PDF (1370 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effects of urokinase thrombolysis combined with tirofiban or ticagrelor antiplatelet therapy in the treatment of acute ST segment elevation myocardial infarction (STEMI). Methods: According to the treatment Methods , 148 cases of patients with STEMI were divided into tirofiban group, ticagrelor group and clopidogrel group. The three groups were treated with urokinase thrombolysis for 7 days. The myocardial reperfusion indexes, cardiac function, myocardial injury markers, inflammation related indicators and 30d adverse events were compared among groups. Results: Compared with clopidogrel group, the ratios of ST segment decline >|50%, grade 3 blood flow of thrombolysis in myocardial infarction (TIMI) and grade 3 myocardial perfusion (TMP) and left ventricular ejection fraction (LVEF) were significantly higher in tirofiban group and ticagrelor group after treatment|while the left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), levels of serum creatine kinase isoenzyme (CK-MB), cardiac troponin (cTnI), high-sensitivity C reactive protein (hs-CRP) and tumor necrosis factor α (TNF-α) were significantly lower (P <|0.05). There were no statistically significant differences between the tirofiban and the ticagrelor group (P >|0.05). There was no significant difference in the incidence of adverse events in 30 days among the three groups (P >|0.05). Conclusion: The application of urokinase thrombolysis combined with tirofiban or ticagrelor antiplatelet therapy in the treatment of STEMI can significantly improve cardiac function and reduce myocardial injury and inflammatory response. The short-term prognosis is similar, and the curative effect of tirofiban and ticagrelor is similar.

Key words： Acute ST segment elevation myocardial infarction Tirofiban Ticagrelor

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LU Chaoling
	ZHANG Xiaoxin
	LIAO Peijuan
	et al

Cite this article:

LU Chaoling,ZHANG Xiaoxin,LIAO Peijuan, et al. Urokinase Thrombolysis Combined with Tirofiban or Ticagrelor Antiplatelet in the Treatment of Acute STEMI[J]. 河北医学, 2017, 23(9): 1444-1447.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2017.09.011 OR http://www.hbyxzzs.cn/EN/Y2017/V23/I9/1444

[1] 蒙绪宁,卢志红,王孟杰,等.早期应用替罗非班对≤60岁急性ST段抬高心肌梗死急诊介入治疗术后心肌微循环灌注的影响[J].广西医科大学学报,2013,30(1):96~98.
[2] 熊斌,冯文伟,林海云,等.急诊PCI应用前列地尔对急性ST段抬高型心肌梗死再灌注的影响[J].湖南师范大学学报(医学版),2015,1(3):79~81.
[3] 王俊乾,车京津,李连,等.急性ST段抬高型心肌梗死PCI术前应用替罗非班的的疗效及安全性[J].山东医药,2015,55(5):44~46.
[4] 过云峰,陈风,高长征,等.替格瑞洛联合替罗非班在老年急性ST段抬高型心肌梗死患者经皮冠状动脉介入治疗中的临床疗效[J].中国老年学杂志,2016,36(19):4755~4757.
[5] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2010,38(8):675~690.
[6] 毛艳阳,王军强,王晨霞,等.替格瑞洛联合溶栓治疗ST段抬高型心肌梗死疗效及对患者心肌损伤标志物与炎性因子水平的影响[J].安徽医药,2016,20(3):551~554.
[7] 王海波,黄宜杰,吴强,等.替格瑞洛与氯吡格雷对急性ST段抬高型心肌梗死的临床疗效对比研究[J].中国循环杂志,2014,29(8):574~577.
[8] 许骥,华琦,胡少东,等.替格瑞洛在老年STEMI患者急诊PCI中的疗效与安全性分析[J].首都医科大学学报,2015,36(1):73~77.
[9] 张莉,顾兴建,陈长弓,等.替格瑞洛与氯吡格雷在STEMI患者PCI治疗中的效果对比[J].中国生化药物杂志,2017,37(3):246~248.
[10] 杨健,罗瑛,李淑均,等.替罗非班不同给药途径对急性心肌梗死患者的临床疗效分析[J].医学临床研究,2015,32(4):718~720.
[11] 魏鹏,杨向军,付强,等.替格瑞洛对急性ST段抬高型心肌梗死患者血清hs-CRP和ESM-1水平的影响及短期预后观察[J].中国动脉硬化杂志,2017,25(3):264~268.
[12] 张健发,于雁飞,黄定,等.替格瑞洛联合替罗非班在ST段抬高型心肌梗死糖尿病患者急诊PCI术中的应用和安全性[J].中国老年学杂志,2017,37(5):1098~1101.